Search / Trial NCT06234605

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Launched by HIBERCELL, INC. · Jan 29, 2024

Trial Information

Current as of October 04, 2024

Recruiting

Keywords

Cc Rcc Belzutifan Kidney Cancer Metastatic Locally Advanced Hc 7366 Welireg™

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Has diagnosis of locally advanced (inoperable) or metastatic RCC with a predominant clear cell component
  • * Be age 18 years or older (male or female) at the time of consent

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Saint Louis, Missouri, United States

Los Angeles, California, United States

New York, New York, United States

Cleveland, Ohio, United States

Seattle, Washington, United States

Tucson, Arizona, United States

Dallas, Texas, United States

Cleveland, Ohio, United States

La Jolla, California, United States

Fairfax, Virginia, United States

Lone Tree, Colorado, United States

Portland, Oregon, United States

Madison, Wisconsin, United States

Saint Paul, Minnesota, United States

Nashville, Tennessee, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0